NexImmune, Inc. (NEXI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NexImmune, Inc. (NEXI) trades at $0.0001. NexImmune, Inc. is a clinical-stage biotechnology company focused on developing T cell immunotherapies for cancer and immune-mediated diseases. Their Artificial Immune Modulation platform drives the development of allogeneic and autologous cell therapies. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NEXI: NEXI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NEXI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on NEXI.
How is this calculated? →NexImmune, Inc. (NEXI) Healthcare & Pipeline Overview
NexImmune, Inc. is a clinical-stage biotechnology firm specializing in T cell immunotherapies, leveraging its Artificial Immune Modulation (AIM) platform to develop novel treatments for cancer and immune-mediated diseases. Their pipeline includes allogeneic and autologous cell therapies currently in Phase I/II clinical trials, targeting acute myeloid leukemia and multiple myeloma.
What Is the Investment Thesis for NEXI?
NexImmune operates in the high-growth biotechnology sector, focusing on innovative T cell immunotherapies. The company's AIM platform represents a novel approach to modulating the immune system, potentially offering advantages over existing cell therapy approaches. Key value drivers include the successful advancement of NEXI-001 and NEXI-002 through clinical trials, demonstrating safety and efficacy in treating AML and MM, respectively. Positive clinical data could lead to partnerships or acquisitions. A potential risk lies in the high attrition rate of clinical-stage drug development and the need for substantial capital to fund ongoing research and clinical trials. The company's small market capitalization and limited cash runway also present financial risks. The company's beta of 5.03 indicates very high volatility.
Based on FMP financials and quantitative analysis
NEXI Key Highlights
NEXI-001 is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia.
- NEXI-002 is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma.
- NEXI-003 is a candidate targeted against HPV-associated malignancies, which is in preclinical stage.
- The company's core technology is its proprietary Artificial Immune Modulation (AIM) platform.
- NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Who Are NEXI's Competitors?
NEXI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals, Inc. | $18.73 | +3.19% | $64.4M | 31 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NEXI's Key Strengths?
Proprietary Artificial Immune Modulation (AIM) platform.
- Pipeline of clinical-stage T cell immunotherapy candidates.
- Experienced management team with expertise in drug development.
- Focus on addressing unmet medical needs in cancer and immune-mediated diseases.
What Are NEXI's Weaknesses?
Limited financial resources and reliance on external funding.
- High attrition rate of clinical-stage drug development.
- Small market capitalization and limited trading volume.
- Dependence on the success of its lead product candidates.
What Could Drive NEXI Stock Higher?
Release of interim data from Phase I/II clinical trials for NEXI-001 in AML.
- Release of interim data from Phase I/II clinical trials for NEXI-002 in MM.
- Advancement of NEXI-003 into Phase I clinical trials.
- Potential partnerships or collaborations with larger pharmaceutical companies.
- Expansion of the AIM platform to new therapeutic areas.
What Are the Key Risks for NEXI?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles and the risk of non-approval.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Limited financial resources and reliance on external funding.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for NEXI?
- Expansion of Clinical Trials: NexImmune has the opportunity to expand the clinical trials for NEXI-001 and NEXI-002 to include a larger patient population and additional clinical sites. This expansion could accelerate the development timeline and increase the likelihood of regulatory approval. The market for AML and MM treatments is substantial, with a global market size estimated at billions of dollars. Successful clinical trials could position NexImmune to capture a significant share of this market.
- Development of NEXI-003: Advancing NEXI-003, the preclinical candidate targeting HPV-associated malignancies, represents a significant growth opportunity. HPV-associated cancers, such as cervical cancer and head and neck cancer, affect a large number of people worldwide. Successful development of NEXI-003 could address a significant unmet medical need and generate substantial revenue for NexImmune. The timeline for this opportunity is dependent on preclinical and clinical trial results.
- Partnerships and Collaborations: NexImmune can pursue partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships could provide access to additional funding, expertise, and resources. The biotechnology industry is characterized by frequent collaborations between smaller companies and larger pharmaceutical firms, offering a viable pathway for growth.
- Expansion into New Therapeutic Areas: The AIM platform has the potential to be applied to a wide range of immune-mediated diseases beyond cancer. NexImmune can explore expanding its pipeline to include therapies for autoimmune diseases, infectious diseases, and other conditions. This expansion would diversify the company's product portfolio and reduce its reliance on oncology.
- Geographic Expansion: NexImmune can expand its operations to new geographic markets, such as Europe and Asia, to access a larger patient population and increase its revenue potential. This expansion would require establishing clinical trial sites and regulatory approvals in the target markets. The global market for immunotherapies is growing rapidly, offering opportunities for companies to expand their reach beyond their domestic market.
What Are NEXI's Competitive Advantages?
- Proprietary Artificial Immune Modulation (AIM) platform.
- Patent protection for its technologies and product candidates.
- Clinical data demonstrating the safety and efficacy of its therapies.
- Expertise in T cell immunotherapy development.
What Does NEXI Do?
NexImmune, Inc., founded in 2011 and headquartered in Gaithersburg, Maryland, is a clinical-stage biotechnology company dedicated to creating therapies with the potential to cure cancer and other life-threatening immune-mediated diseases. The company's core technology is its proprietary Artificial Immune Modulation (AIM) platform, which utilizes nanoparticles to modulate and direct T cell responses. This platform is designed to harness the body's own immune system to fight disease. NexImmune's lead product candidates include NEXI-001, an allogeneic cell therapy currently in Phase I/II clinical trials for acute myeloid leukemia (AML), and NEXI-002, an autologous cell therapy also in Phase I/II trials for relapsed and/or refractory multiple myeloma (MM). Additionally, NEXI-003, a preclinical candidate, targets HPV-associated malignancies. NexImmune's focus is on developing innovative immunotherapies that can provide durable responses and improve patient outcomes in areas with significant unmet medical needs. The company's research and development efforts are centered on advancing its AIM platform and expanding its pipeline of T cell-based therapies.
What Products and Services Does NEXI Offer?
- Develops T cell immunotherapies for cancer and immune-mediated diseases.
- Utilizes the Artificial Immune Modulation (AIM) platform to direct T cell responses.
- Conducts Phase I/II clinical trials for NEXI-001 in acute myeloid leukemia.
- Conducts Phase I/II clinical trials for NEXI-002 in relapsed/refractory multiple myeloma.
- Develops NEXI-003, a preclinical candidate targeting HPV-associated malignancies.
- Researches and develops novel immunotherapies to improve patient outcomes.
How Does NEXI Make Money?
- Develops and patents novel T cell immunotherapy technologies.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approval for its therapies from agencies like the FDA.
- Potentially commercializes its therapies directly or through partnerships with larger pharmaceutical companies.
What Industry Does NEXI Operate In?
NexImmune operates within the competitive biotechnology industry, which is characterized by rapid innovation and high investment in research and development. The market for cancer immunotherapies is experiencing significant growth, driven by the increasing prevalence of cancer and the demand for more effective and less toxic treatments. Key trends include the development of personalized therapies, the use of combination therapies, and the exploration of new immune targets. NexImmune's AIM platform positions it to potentially compete with established players in the cell therapy space, such as Gilead (through its acquisition of Kite Pharma) and Novartis, as well as other emerging biotechnology companies focused on immunotherapy.
Who Are NEXI's Key Customers?
- Patients with acute myeloid leukemia (AML).
- Patients with relapsed and/or refractory multiple myeloma (MM).
- Potentially, patients with HPV-associated malignancies in the future.
- Healthcare providers who treat these patient populations.
Company Profile
NexImmune, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Gaithersburg, US. The company is led by CEO Craig R. Jalbert. NEXI has traded publicly since 2021.
Insider Activity
The most recent 11 insider filings for NexImmune, Inc. break down as 5 sales and 6 purchases. On net that is roughly 199K shares acquired (about $38K) — insiders putting money in tends to read as conviction.
Forward Outlook
Wall Street analysts project NexImmune, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1.01.
Financial Health
NexImmune, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NEXI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in NexImmune's potential.
- Community sentiment has shifted positively, with discussions highlighting recent advancements in their immunotherapy technology.
- Analysts are noting increased interest from institutional investors, which can lead to greater market validation of NexImmune's business model.
- The company's recent partnerships in research collaborations are seen as a strong endorsement of its innovative approach to immune modulation.
Bear Case
- Concerns about the competitive landscape in the immunotherapy sector are prevalent, with many pointing to larger players with established products.
- Recent clinical trial results did not meet some market expectations, leading to skepticism about the company's near-term growth trajectory.
- Social sentiment reflects caution, with discussions around the sustainability of NexImmune's business model given the high costs associated with R&D.
- Market perception is mixed, as some investors remain wary of biotech stocks due to regulatory uncertainties and funding challenges.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NEXI Latest News
No recent news available for NEXI.
NEXI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NEXI.
Price Targets
Wall Street price target analysis for NEXI.
NEXI MoonshotScore
What does this score mean?
The MoonshotScore rates NEXI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John Trainer
CEO
John Trainer serves as the CEO of NexImmune, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held leadership positions at various companies, focusing on strategic planning, business development, and commercialization of novel therapies. His expertise spans across multiple therapeutic areas, including oncology and immunology. Trainer's experience also includes fundraising and investor relations.
Track Record: Under John Trainer's leadership, NexImmune has advanced its lead product candidates, NEXI-001 and NEXI-002, through Phase I/II clinical trials. He has overseen the development of the company's AIM platform and the expansion of its pipeline. Trainer has also been instrumental in securing funding for the company's research and development efforts. The company currently has 6 employees.
NEXI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NexImmune may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Potential for fraud and manipulation.
- Low trading volume and liquidity.
- Higher price volatility compared to exchange-listed stocks.
- Limited access to company information and financial reports.
- Verify the company's registration and legal status.
- Obtain and review audited financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the company's capital structure and funding sources.
- Assess the risks associated with the company's industry and operations.
- Consult with a financial advisor before making any investment decisions.
- Company has a functioning website with detailed information.
- Company has patents or intellectual property related to its technology.
- Company has published scientific papers or presented at conferences.
- Company has partnerships or collaborations with reputable organizations.
- Company has a board of directors with relevant experience.
Common Questions About NEXI (Healthcare)
What does NexImmune, Inc. do?
NexImmune, Inc. is a clinical-stage biotechnology company focused on developing innovative T cell immunotherapies for cancer and other life-threatening immune-mediated diseases. The company's proprietary Artificial Immune Modulation (AIM) platform utilizes nanoparticles to modulate and direct T cell responses, harnessing the body's own immune system to fight disease.
What are the main risks for NEXI?
The main risks for NexImmune include the inherent uncertainties of clinical-stage drug development, such as the risk of clinical trial failures or delays. The company also faces regulatory hurdles and the potential for non-approval of its product candidates. Competition from established pharmaceutical companies and other biotechnology firms is another significant risk.
What are the key factors to evaluate for NEXI?
Evaluate NEXI on fundamentals, analyst consensus, and risk factors. NexImmune operates in the high-growth biotechnology sector, focusing on innovative T cell immunotherapies. Not financial advice.
How frequently does NEXI data refresh on this page?
NEXI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NEXI's recent stock price performance?
NexImmune, Inc. (NEXI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Artificial Immune Modulation (AIM) platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NEXI overvalued or undervalued right now?
NexImmune, Inc. (NEXI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NEXI before investing?
Before investing in NexImmune, Inc. (NEXI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding NEXI to a portfolio?
Key strength of NexImmune, Inc. (NEXI): Proprietary Artificial Immune Modulation (AIM) platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.